SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Rep. Pramila Jayapal (D-Wash.) is leading House Democratic progressives against a moderate drug pricing bill that caucus members say is insufficient. (Photo: @Public_Citizen/Twitter)
'Stakes Higher Than They Appear' as Progressive Caucus Battles Pelosi Over Drug-Pricing Bill in House
"Drug prices are crushing American families," Sen. Elizabeth Warren said, but Speaker Nancy Pelosi and her moderate allies appear insistent on keeping legislation to fix the issue contained to only 31 drugs.
Dec 09, 2019
A brewing standoff between the progressive and moderate wings of the majority Democratic party in the U.S. House of Representatives over a drug pricing bill is exposing a power struggle within the caucus and could preview larger ideological battles ahead.
That's according to reporting Monday from The Intercept's Ryan Grim and The American Prospect's David Dayen on the potential for a blowout fight between the Congressional Progressive Caucus (CPC) and House Speaker Nancy Pelosi (D-Calif.) and her moderate allies on a drug pricing bill, H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act.
According to Grim and Dayen, the CPC is interested in possibly using the caucus' power in the Rules Committee to block the bill over centrist Democrats' refusal to bend on the bill--a strategy reminiscent of the behavior of the GOP Freedom Caucus, which built itself into a force on the House floor due to ideological rigidity and a willingness to use procedure as a weapon.
As Bloomberg News reporter Sahil Kapur noted on Twitter, that behavior isn't known as a CPC tactic--at least not in the past--and that's had consequences.
"The Progressive Caucus doesn't usually withhold votes as a bloc to twist Dem leaders' arm, unlike the GOP's Freedom Caucus," said Kapur. "Hence this Congress the balance of power has remained where it usually is in the House Dem caucus: with moderates."
At issue is the strength and scope of the bill, which at the moment would only give "authority to the government to negotiate lower prices for more than a mere 25 drugs." Progressives want stronger legislation that would include an amendment from Rep. Pramila Jayapal (D-Wash.) that would prevent drug companies from spiking prices for profit and amendments from Rep. Lloyd Doggett (D-Texas) which would have increased the number of drugs covered in the law and guaranteed the 30 million Americans withouthealth insurance would benefit from the legislation.
The CPC began whipping members against the bill on Friday after it was gutted by Pelosi's office, setting up Tuesday's showdown.
As Dayen and Grim explain in their piece, the fight over H.R. 3 is part of an ongoing struggle in the Democratic caucus:
The relative weakness of the bill coming to the House floor makes a mockery of the health care debate unfolding on the presidential campaign trail. While 2020 Democratic hopefuls debate a sweeping, comprehensive reform of the health care system, Democrats in the House are having trouble giving authority to the government to negotiate lower prices for more than a mere 25 drugs. The gap between the two debates could hardly be greater, even though Democrats in the House have a free hand policy-wise: After all, the bill has little chance of passing the Senate and becoming law, so it's largely a messaging exercise.
All year long, the relationship between the Progressive Caucus and House leadership has simmered behind the scenes, emerging only in fitful moments, like in July when Pelosi resigned to passing a border supplemental spending bill that added few checks to the Trump administration's cruel caging-of-children policies. The impeachment fight has mostly created unity among House Democrats, against a common enemy's efforts to abuse the power of the presidency by leveraging foreign aid in order to damage a domestic political opponent. But lingering in the background all year has been the drug-pricing fight.
Grim and Dayen wrote on Monday that the CPC's decision could have ramifications on how the House decides on policy in the next year and beyond.
"It's not hyperbole to call the fight a potential bend point in the history of the Democratic Party, with stakes much higher than they appear," they wrote.
In comment to The Hill, a Pelosi aide sent a veiled warning to the CPC and expressed confidence that the moderates would win the day.
"Representatives Pocan and Jayapal are gravely misreading the situation if they try to stand in the way of the overwhelming hunger for HR3 within the House Democratic Caucus and among progressive Members," said the aide. "The Lower Drug Costs Now Act will pass next week."
House Majority Leader Steny Hoyer (D-Md.), however, told Politico he was "certainly" concerned progressives would stymie the bill.
The stronger legislation has the support of Democratic presidential candidates Sen. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.). While the pair are unlikely to get the chance to vote on H.R. 3--Senate Majority Leader Mitch McConnell (R-Ky.) is expected to let the legislation die in committee rather than bring it to a vote--a strong bill sends a message to party leaders and the public.
"The Lower Drug Costs Now Act goes after Big Pharma's greed and makes important investments in community health centers and dental care for those on Medicare," Sanders tweeted Monday evening. "@USProgressives are fighting to make this bill even stronger, and I support their efforts."
"A bill to fix this shouldn't work for only some drugs or some people--it should help everyone afford lifesaving treatments," Warren tweeted Saturday.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
bernie sandersbig pharmacongressional progressive caucuselizabeth warrenmark pocanmedicare for allnancy pelosipramila jayapal
A brewing standoff between the progressive and moderate wings of the majority Democratic party in the U.S. House of Representatives over a drug pricing bill is exposing a power struggle within the caucus and could preview larger ideological battles ahead.
That's according to reporting Monday from The Intercept's Ryan Grim and The American Prospect's David Dayen on the potential for a blowout fight between the Congressional Progressive Caucus (CPC) and House Speaker Nancy Pelosi (D-Calif.) and her moderate allies on a drug pricing bill, H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act.
According to Grim and Dayen, the CPC is interested in possibly using the caucus' power in the Rules Committee to block the bill over centrist Democrats' refusal to bend on the bill--a strategy reminiscent of the behavior of the GOP Freedom Caucus, which built itself into a force on the House floor due to ideological rigidity and a willingness to use procedure as a weapon.
As Bloomberg News reporter Sahil Kapur noted on Twitter, that behavior isn't known as a CPC tactic--at least not in the past--and that's had consequences.
"The Progressive Caucus doesn't usually withhold votes as a bloc to twist Dem leaders' arm, unlike the GOP's Freedom Caucus," said Kapur. "Hence this Congress the balance of power has remained where it usually is in the House Dem caucus: with moderates."
At issue is the strength and scope of the bill, which at the moment would only give "authority to the government to negotiate lower prices for more than a mere 25 drugs." Progressives want stronger legislation that would include an amendment from Rep. Pramila Jayapal (D-Wash.) that would prevent drug companies from spiking prices for profit and amendments from Rep. Lloyd Doggett (D-Texas) which would have increased the number of drugs covered in the law and guaranteed the 30 million Americans withouthealth insurance would benefit from the legislation.
The CPC began whipping members against the bill on Friday after it was gutted by Pelosi's office, setting up Tuesday's showdown.
As Dayen and Grim explain in their piece, the fight over H.R. 3 is part of an ongoing struggle in the Democratic caucus:
The relative weakness of the bill coming to the House floor makes a mockery of the health care debate unfolding on the presidential campaign trail. While 2020 Democratic hopefuls debate a sweeping, comprehensive reform of the health care system, Democrats in the House are having trouble giving authority to the government to negotiate lower prices for more than a mere 25 drugs. The gap between the two debates could hardly be greater, even though Democrats in the House have a free hand policy-wise: After all, the bill has little chance of passing the Senate and becoming law, so it's largely a messaging exercise.
All year long, the relationship between the Progressive Caucus and House leadership has simmered behind the scenes, emerging only in fitful moments, like in July when Pelosi resigned to passing a border supplemental spending bill that added few checks to the Trump administration's cruel caging-of-children policies. The impeachment fight has mostly created unity among House Democrats, against a common enemy's efforts to abuse the power of the presidency by leveraging foreign aid in order to damage a domestic political opponent. But lingering in the background all year has been the drug-pricing fight.
Grim and Dayen wrote on Monday that the CPC's decision could have ramifications on how the House decides on policy in the next year and beyond.
"It's not hyperbole to call the fight a potential bend point in the history of the Democratic Party, with stakes much higher than they appear," they wrote.
In comment to The Hill, a Pelosi aide sent a veiled warning to the CPC and expressed confidence that the moderates would win the day.
"Representatives Pocan and Jayapal are gravely misreading the situation if they try to stand in the way of the overwhelming hunger for HR3 within the House Democratic Caucus and among progressive Members," said the aide. "The Lower Drug Costs Now Act will pass next week."
House Majority Leader Steny Hoyer (D-Md.), however, told Politico he was "certainly" concerned progressives would stymie the bill.
The stronger legislation has the support of Democratic presidential candidates Sen. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.). While the pair are unlikely to get the chance to vote on H.R. 3--Senate Majority Leader Mitch McConnell (R-Ky.) is expected to let the legislation die in committee rather than bring it to a vote--a strong bill sends a message to party leaders and the public.
"The Lower Drug Costs Now Act goes after Big Pharma's greed and makes important investments in community health centers and dental care for those on Medicare," Sanders tweeted Monday evening. "@USProgressives are fighting to make this bill even stronger, and I support their efforts."
"A bill to fix this shouldn't work for only some drugs or some people--it should help everyone afford lifesaving treatments," Warren tweeted Saturday.
A brewing standoff between the progressive and moderate wings of the majority Democratic party in the U.S. House of Representatives over a drug pricing bill is exposing a power struggle within the caucus and could preview larger ideological battles ahead.
That's according to reporting Monday from The Intercept's Ryan Grim and The American Prospect's David Dayen on the potential for a blowout fight between the Congressional Progressive Caucus (CPC) and House Speaker Nancy Pelosi (D-Calif.) and her moderate allies on a drug pricing bill, H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act.
According to Grim and Dayen, the CPC is interested in possibly using the caucus' power in the Rules Committee to block the bill over centrist Democrats' refusal to bend on the bill--a strategy reminiscent of the behavior of the GOP Freedom Caucus, which built itself into a force on the House floor due to ideological rigidity and a willingness to use procedure as a weapon.
As Bloomberg News reporter Sahil Kapur noted on Twitter, that behavior isn't known as a CPC tactic--at least not in the past--and that's had consequences.
"The Progressive Caucus doesn't usually withhold votes as a bloc to twist Dem leaders' arm, unlike the GOP's Freedom Caucus," said Kapur. "Hence this Congress the balance of power has remained where it usually is in the House Dem caucus: with moderates."
At issue is the strength and scope of the bill, which at the moment would only give "authority to the government to negotiate lower prices for more than a mere 25 drugs." Progressives want stronger legislation that would include an amendment from Rep. Pramila Jayapal (D-Wash.) that would prevent drug companies from spiking prices for profit and amendments from Rep. Lloyd Doggett (D-Texas) which would have increased the number of drugs covered in the law and guaranteed the 30 million Americans withouthealth insurance would benefit from the legislation.
The CPC began whipping members against the bill on Friday after it was gutted by Pelosi's office, setting up Tuesday's showdown.
As Dayen and Grim explain in their piece, the fight over H.R. 3 is part of an ongoing struggle in the Democratic caucus:
The relative weakness of the bill coming to the House floor makes a mockery of the health care debate unfolding on the presidential campaign trail. While 2020 Democratic hopefuls debate a sweeping, comprehensive reform of the health care system, Democrats in the House are having trouble giving authority to the government to negotiate lower prices for more than a mere 25 drugs. The gap between the two debates could hardly be greater, even though Democrats in the House have a free hand policy-wise: After all, the bill has little chance of passing the Senate and becoming law, so it's largely a messaging exercise.
All year long, the relationship between the Progressive Caucus and House leadership has simmered behind the scenes, emerging only in fitful moments, like in July when Pelosi resigned to passing a border supplemental spending bill that added few checks to the Trump administration's cruel caging-of-children policies. The impeachment fight has mostly created unity among House Democrats, against a common enemy's efforts to abuse the power of the presidency by leveraging foreign aid in order to damage a domestic political opponent. But lingering in the background all year has been the drug-pricing fight.
Grim and Dayen wrote on Monday that the CPC's decision could have ramifications on how the House decides on policy in the next year and beyond.
"It's not hyperbole to call the fight a potential bend point in the history of the Democratic Party, with stakes much higher than they appear," they wrote.
In comment to The Hill, a Pelosi aide sent a veiled warning to the CPC and expressed confidence that the moderates would win the day.
"Representatives Pocan and Jayapal are gravely misreading the situation if they try to stand in the way of the overwhelming hunger for HR3 within the House Democratic Caucus and among progressive Members," said the aide. "The Lower Drug Costs Now Act will pass next week."
House Majority Leader Steny Hoyer (D-Md.), however, told Politico he was "certainly" concerned progressives would stymie the bill.
The stronger legislation has the support of Democratic presidential candidates Sen. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.). While the pair are unlikely to get the chance to vote on H.R. 3--Senate Majority Leader Mitch McConnell (R-Ky.) is expected to let the legislation die in committee rather than bring it to a vote--a strong bill sends a message to party leaders and the public.
"The Lower Drug Costs Now Act goes after Big Pharma's greed and makes important investments in community health centers and dental care for those on Medicare," Sanders tweeted Monday evening. "@USProgressives are fighting to make this bill even stronger, and I support their efforts."
"A bill to fix this shouldn't work for only some drugs or some people--it should help everyone afford lifesaving treatments," Warren tweeted Saturday.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.